Evaluating BPT567 for patients with advanced solid tumors
Official title: A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors
Run by Bright Peak Therapeutics Inc · NCT06779851 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new treatment called BPT567 to see if it's safe and how well it works for people with advanced solid tumors who haven't responded to other therapies.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Bright Peak Therapeutics Inc Industry-sponsored |
| Drugs / interventions | radiation, prednisone |
| Locations | 3 sites (Scottsdale, Arizona and 2 other locations) |
| Trial ID | NCT06779851 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with advanced solid tumors that are locally advanced or metastatic and have progressed after standard treatments.
✕Probably not a fit
Patients who have recently received systemic therapy or investigational agents may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1 clinical trial is designed to assess the safety and tolerability of BPT567 in patients with advanced solid tumors. It involves a multicenter, open-label approach with dose escalation and expansion to determine the maximum tolerated dose and pharmacokinetics of the treatment. Eligible participants will have measurable disease and must have previously progressed on standard therapies. The study aims to establish a recommended dose for future cohorts.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors who have limited treatment alternatives.
How similar studies have gone: Other studies evaluating similar investigational therapies have shown promise, but this specific approach with BPT567 is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female aged ≥18 years at the time of signing informed consent form * Measurable disease per RECIST 1.1 * Histologically- or cytologically-diagnosed, locally advanced unresectable or metastatic solid tumor. Progressed or recurred after previously having received approved standard of care agents that are approved and available in their local geography. * ECOG Performance status of 0 or 1 * Life expectancy of at least 3 months * Adequate organ and marrow function * Contraception during study participation, as applicable Exclusion Criteria: * Has received systemic small molecule therapy or radiation therapy within 28 days prior to the first dose. * Treatment with biologic agents including anti-PD-1 or PD-L1 antibodies for less than 6 weeks or 5 half-lives, whichever is shorter, prior to first dose. * Received any investigational agent less than 28 days or 5 half-lives, whichever is shorter, prior to the first dose. * Treatment with another IL-18 therapy. * Received systemic immunosuppressive agents greater than the equivalent of prednisone 10mg daily within 14 days of the study, though inhaled, intranasal, topical or intra-articular corticosteroids are allowed. * Certain clinically significant intercurrent disease. * Primary immune deficiency. * Active untreated brain or spine metastasis or leptomeningeal metastases. * Known HIV seroposivitiy, although patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents are permitted. * Active hepatitis A or acute or chroming hepatitis B or C infection. * Received a live virus vaccine within 30 days of enrollment or a COVD vaccine within 14 days.
Where it's running
-
Honor Health Research Institute
Scottsdale, Arizona, United States Recruiting -
Start Midwest
Grand Rapids, Michigan, United States Recruiting -
Carolina BioOncology Institute
Huntersville, North Carolina, United States Recruiting
Study contacts
- Study coordinator: Sujatha Venugopal Prasad, M. Sc.
- Email: sprasad@brightpeaktx.com
- Phone: +1(408)357- 4546
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
AK157D1 injection for advanced solid tumors
A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
MK-2010 alone or with other treatments for advanced solid tumors
This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.
-
Whole-Body Infrared Heating for Advanced Solid Tumors
This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.